Nadia Yousaf

4.7k total citations · 1 hit paper
48 papers, 1.2k citations indexed

About

Nadia Yousaf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Nadia Yousaf has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Nadia Yousaf's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). Nadia Yousaf is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). Nadia Yousaf collaborates with scholars based in United Kingdom, United States and Spain. Nadia Yousaf's co-authors include James Larkin, Alexander R. Lyon, Javid J. Moslehi, Nicolò Matteo Luca Battisti, Ian Pavord, Surinder S. Birring, Kai K. Lee, Sanjay Popat, Paul Blanche and Sérgio Matos and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Nadia Yousaf

45 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune checkpoint inhibitors and cardiovascular toxicity

2018 390 citations Alexander R. Lyon, Nadia Yousaf et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Nadia Yousaf

Since Specialization

Citations

This map shows the geographic impact of Nadia Yousaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Yousaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Yousaf more than expected).

Fields of papers citing papers by Nadia Yousaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Yousaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Yousaf. The network helps show where Nadia Yousaf may publish in the future.

Co-authorship network of co-authors of Nadia Yousaf

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Yousaf. A scholar is included among the top collaborators of Nadia Yousaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Yousaf. Nadia Yousaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery 2024 ·Lung Cancer ·(unknown), (unknown), Faisal Rehman, (unknown), (unknown), (unknown), (unknown), Nadia Yousaf, (unknown), Carol Tan, Jeremy Smelt, Ian Hunt, Simon Jordan, Sofina Begum, Jaishree Bhosle, Anna Minchom, (unknown), Sanjay Popat, Mary O’Brien, Michael Davidson	0
2	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond 2021 ·Lung Cancer ·Kroopa Joshi, (unknown), (unknown), (unknown), Nadia Yousaf, Sanjay Popat, Michael Davidson, Jaishree Bhosle, Mary O’Brien, Anna Minchom	5
3	Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications 2021 ·Frontiers in Medicine ·Sumeet Hindocha, (unknown), Merina Ahmed, (unknown), Bhupinder Sharma, Nadia Yousaf, Philip L. Molyneaux, Benjamin Hunter, (unknown), Wanyuan Cui, Michael Davidson, Jaishree Bhosle, Anna Minchom, Imogen Locke, Fiona McDonald, Mary O’Brien, Sanjay Popat, Richard Lee	5
4	180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19 2021 ·Journal of Thoracic Oncology ·Wanyuan Cui, (unknown), (unknown), Jaishree Bhosle, Anna Minchom, Michael Davidson, (unknown), Imogen Locke, Nadia Yousaf, Sanjay Popat, Mary O’Brien	3
5	Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma 2020 ·Clinical Medicine ·(unknown), Nadia Yousaf, Daniel L. Morganstein	26
6	Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma 2020 ·ESMO Open ·(unknown), Lavinia Spain, Lewis Au, James J. Clark, (unknown), Stefan Diem, (unknown), Samra Turajlic, Nick Powell, James Larkin, Nadia Yousaf	30
7	1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience 2020 ·Annals of Oncology ·Wanyuan Cui, (unknown), Iris Faull, Rebecca J. Nagy, (unknown), Anna Minchom, Jaishree Bhosle, Nadia Yousaf, Mary O’Brien, Sanjay Popat	1
8	“Triggers” for early palliative care referral in patients with cancer: a review of urgent unplanned admissions and outcomes 2019 ·Supportive Care in Cancer ·(unknown), Nadia Yousaf, Joanne Droney	24
9	149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction 2018 ·Journal of Thoracic Oncology ·(unknown), Mary O’Brien, Jaishree Bhosle, Nadia Yousaf, Rajiv Kumar, Sanjay Popat, (unknown)	3
10	Immune checkpoint inhibitors and cardiovascular toxicity breakdown → 2018 ·The Lancet Oncology ·Alexander R. Lyon, Nadia Yousaf, Nicolò Matteo Luca Battisti, Javid J. Moslehi, James Larkin	390
11	Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI) 2016 ·Annals of Oncology ·Lavinia Spain, Stefan Diem, Komel Khabra, Samra Turajlic, Martin Gore, Nadia Yousaf, James Larkin	5
12	Predictors of objective cough frequency in pulmonary sarcoidosis 2016 ·European Respiratory Journal ·Aish Sinha, Kai K. Lee, Gerrard F. Rafferty, Nadia Yousaf, Ian Pavord, James Galloway, Surinder S. Birring	39
13	The cost of ipilimumab toxicity 2015 ·Melanoma Research ·Nadia Yousaf, Michael Davidson, E. Goode, (unknown), (unknown), Martin Gore, James Larkin	17
14	First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma 2015 ·PubMed ·Nadia Yousaf, S.J. Harris, Juan Martín-Liberal, Susannah Stanway, Mark Linch, (unknown), (unknown), Komel Khabra, Cyril Fisher, Jonathan Noujaim, Ian Judson, Charlotte Benson	10
15	The long term outcome of patients with unexplained chronic cough 2012 ·Respiratory Medicine ·Nadia Yousaf, (unknown), Surinder S. Birring, Ian Pavord	37
16	The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute) 2011 ·PubMed ·Nadia Yousaf, Kai K. Lee, (unknown), Ian Pavord, Surinder S. Birring	64
17	Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience 2011 ·British Journal of Cancer ·Thomas K. Waddell, (unknown), Anastasia Constantinidou, Nadia Yousaf, S. Ashley, Marina Parton, Mark Allen, Naureen Starling, P. Papadopoulos, Mary O’Brien, Ian Smith, Stephen Johnston	20
18	THE LONG-TERM OUTCOME OF PATIENTS WITH UNEXPLAINED CHRONIC COUGH 2009 ·Thorax ·Nadia Yousaf, Surinder S. Birring, Ian Pavord	1
19	FACTORS AFFECTING COUGH FREQUENCY IN A MIXED POPULATION 2009 ·Thorax ·Nadia Yousaf, Sérgio Matos, Surinder S. Birring, Ian Pavord	3
20	NORMAL RANGE FOR 24-HOUR COUGH FREQUENCY 2008 ·Thorax ·(unknown), Nadia Yousaf, Sérgio Matos, Ian Pavord	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact